1. South Korea Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
BioBijou Co., Ltd.

BioBijou Co., Ltd.

KKRX:489460
12,330.00
KRW
+630.00
(+5.38%)
428.81EPS
14.14P/E
92.22BMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
29,908.03
60,596.51
1,593.96
2,597.18
2,044.9
1,899.48
Basic EPS, GAAP
358
1,993
308
630
298
433.62
Free Cash Flow per Basic Share
-14,519.36
4,898.07
371.81
33.35
-255.3
-23.14
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
212.12
523.12
764.8
2,057.05
4,118.42
4,249.69
Tangible Book Value per Share
210.71
521.45
760.78
2,048.96
4,083.17
4,215.39
Basic Weighted Avg Shares
- -
- -
11
11
14
15
Sales/Revenue/Turnover
8,742
21,065
17,130
29,633
28,491
28,558
Operating Margin (%)
4.94
17.28
30.15
31.14
14.84
17.52
Depreciation Expense
438
550
587
700
774
779
Net Income, GAAP
105
693
3,310
7,188
4,152
6,519
Effective Tax Rate (%)
1.07
36.22
21.7
19.95
16.94
19.91
Profit Margin (%)
1.2
3.29
19.32
24.26
14.57
22.83
Working Capital
3,778
4,364
5,030
24,145
46,060
48,677
LT Debt
4,136
3,422
187
102
190
138
Total Equity
3,191
7,870
11,506
30,947
61,980
63,948
Return on Invested Capital (%)
- -
21.57
20.4
23.88
7.26
6.26
Return on Capital (%)
- -
9.38
19.62
25.28
8.74
10.39
Return on Common Equity (%)
- -
12.53
34.17
33.86
8.94
10.42

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
184
162
242
LT Borrowings
- -
- -
- -
LT Finance Leases
190
157
138
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
202,799
118,550
92,222

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
47,637
52,174
52,047
Cash, Cash Equivalents & STI
18,697
27,361
15,448
Accounts Receivable, Net
14,046
13,755
16,291
Inventories
5,415
5,863
4,677
Total Current Liabilities
1,578
4,187
3,371
Payables & Accruals
- -
- -
- -
ST Debt
184
162
242
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
100.28%
Free Cash Flow
- -
- -
-1,034.88%
Net Income, GAAP
- -
- -
-42.24%
Sales/Revenue/Turnover
- -
- -
-3.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
7,052
6,935
9,243
29,633
2025
11,586
6,237
6,640
4,027
28,491
2026
8,015
9,876
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
53
115
223.7
630
2025
142
42
162.06
-90.33
298
2026
193.05
169
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jun-Ho Yang
Full Time Employees
51
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Hanam-si South Korea
IPO Date
May 20, 2025
Website
biobijou.co.kr
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
BioBijou Co., Ltd. is a South Korea-based biotechnology and medical aesthetics company engaged in the research, development, manufacturing, and commercialization of aesthetic medical devices, biomaterials, and advanced dermatological solutions. The company operates through specialized business segments, offering a comprehensive portfolio of aesthetic and regenerative products, including hyaluronic acid (HA) dermal fillers for facial tissue augmentation, contouring, and deep wrinkle correction; polynucleotide (PN) and polydeoxyribonucleotide (PDRN) skin boosters designed for cellular regeneration, skin elasticity improvement, and tissue repair; polydioxanone (PDO) and polycaprolactone (PCL) lifting threads for non-surgical facial rejuvenation; specialized medical consumables, such as precision mesotherapy multi-needles and micro-cannulas; and clinical-grade cosmeceuticals, including post-procedural regenerative creams, concentrated anti-aging serums, and soothing biocellulose masks. In addition to its proprietary branded portfolio, BioBijou provides comprehensive original equipment manufacturing (OEM) and original design manufacturing (ODM) services, encompassing formulation engineering, quality assurance, regulatory compliance, and customized packaging for international aesthetic brands and healthcare distributors. In recent developments, BioBijou completed its public listing on the Korea Exchange (KRX: 489460) to strengthen its capital base and accelerate international market expansion. The company has also expanded its cGMP-compliant manufacturing infrastructure to scale production capacity for its next-generation dermal filler and PN-based skin rejuvenation lines, established strategic distribution partnerships across Southeast Asia, Europe, the Middle East, and Latin America, and advanced strategic R&D initiatives targeting composite biomaterials and exosome-based regenerative aesthetics. Founded in 2018, BioBijou Co., Ltd. is headquartered in South Korea and serves medical clinics, dermatologists, plastic surgery centers, and distributor networks across domestic and international markets.